Search
Login
Register
Menu
Last issue
Home
News
CongressUpdate
Guidelines
Specials
Links
Reimbursement News
All
All
BJH articles
Blog articles
Specials
Search
Forgot Password?
Not a member yet? Register here
Home
/
General
/ Article: SHOULD WE MEASURE DOACS?
“Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer” has been added to your cart.
View cart
Article: SHOULD WE MEASURE DOACS?
€
3.03
Article: SHOULD WE MEASURE DOACS? quantity
Add to cart
SKU:
product-article-23695
Category:
General
Description
Description
SHOULD WE MEASURE DOACS?
Related products
Article: Highlights in squamous cell carcinoma of the head and neck
€
3.03
Add to cart
Article: Highlights in melanoma
€
3.03
Add to cart
Article: Highlights in breast cancer
€
3.03
Add to cart
1 year subscription print edition of the Belgian Journal of Hematology (BJH)
€
209.83
Add to cart